<sup>18</sup>F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging.
Authors: Miles Hsu, Xinhe Shan, Austin Pantel, Samuel U Takvorian, Jeffrey Shevach, Vivek Narayan, Neha Vapiwala, David J. Vaughn, Naomi B. Haas
Journal: Journal of Clinical Oncology (2023)

58 Background: 18 F-DCFPyL recently gained FDA approval for the staging of biochemically recurrent prostate cancer (PCa). After 18 F-DCFPyL became available at our NCI-Designated Comprehensive Cancer Center, 164 PCa pts underwent imaging by 5/2022. Given its novelty, the clinical utility of 18 F-DCFPyL versus conventional imaging (CI) is not well-defined. We evaluated the concordance and treatment impact of 18 F-DCFPyL compared to CI in suspected first biochemical recurrence (BCR) and upstaging rates of 18 F-DCFPyL in initial staging. Methods: The electronic medical record was queried to identify 18 F-DCFPyL scans performed at our center. We selected patients (pts) with PSA recurrence after definitive frontline therapy or those undergoing initial staging. CI was within 3 months of 18 F-DCFPyL. Concordance between CI and 18 F-DCFPyL was assessed, with probable disease defined through assessments by the radiologist and treating oncologist and the clinical setting. Provider notes were used to capture anticipated treatment plans before and after 18 F-DCFPyL. Results: For suspected BCR 30 pts had CI and 6 had two types of CI. The majority (n = 20) were MRIs of the prostate/pelvis. The remainder were nuclear bone scans (n = 4), body CTs (n = 4), 18 F-fluciclovine scans (n = 3), FDG-PET (n = 1), and spinal imaging (n = 3). Discordant findings were present for 12/30 patients in shared imaging fields, of which 7 had likely disease captured solely on 18 F-DCFPyL, 1 instance of disease missed on 18 F-DCFPyL, and 4 instances where findings of uncertain malignant potential on CI were not tracer-avid on 18 F-DCFPyL. The missed disease on 18 F-DCFPyL was a PIRADS 4 prostate lesion captured on MRI. In this group, 4 cases of pelvic nodal lesions were identified on 18 F-DCFPyL and not MRI. 18 F-DCFPyL influenced treatment plans in 4/30 cases. Therapy was selected as follows: local salvage radiation (RT) was chosen after rule-out of systemic disease, RT was restricted to the prostate bed after a culprit lesion was found, and observation was chosen (n = 2) after disease was ruled out on PSMA-PET. For initial staging, 15 pts were thought to have prostate-only disease. On 18 F-DCFPyL, 3/15 were upstaged to distant metastatic disease and 2/15 were upstaged to pelvic nodal disease. Three pts were thought to have extra-prostatic pelvic disease, of which 1/3 were upstaged to distant metastatic disease on 18 F-DCFPyL. Conclusions: In the BCR setting, in which disease is often low volume, 18 F-DCFPyL frequently adds valuable guidance. In our cohort 18 F-DCFPyL captured additional pelvic nodal disease and helped clarify equivocal imaging, limiting unnecessary treatment. For initial staging, the 33% of pts upstaged is substantial, and further data will show whether subsequent changes in management affect outcomes. Limitations include inability to verify disease histologically and to forecast treatment decisions if PSMA-PET were not available.